Ruhe angesagt, oder ?? Mal sehen was die Nasdaq heute macht !
WBA Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Walgreens Boots Alliance to Sycamore Partners
Published
Mar 6, 2025 7:26pm EST
MONSEY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Walgreens Boots Alliance, Inc. (Nasdaq: WBA) (“Walgreens”) to Sycamore Partners (“Sycamore”) for $11.45 per share in cash, plus potentially up to an additional $3.00 per share in cash from future monetization of WBA’s VillageMD businesses.
Notably, as detailed below, the sale price is below the price target for Walgreens of at least two Wall Street analysts even including the potential additional $3.00 per share in cash (source: TipRanks).
As further detailed below, several shareholders on SeekingAlpha have expressed extreme disappointment in the sale price.
If you remain a Walgreens shareholder and question the fairness of the price, you may contact our firm at the following link to discuss your legal rights at no charge:
https://wohlfruchter.com/cases/walgreens-boots-alliance/
Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com.
Why is there an investigation?On March 6, 2025, after the markets closed, Walgreens announced that it had agreed to be sold to Sycamore for $11.45 per share in cash, plus potentially up to an additional $3.00 per share in cash from future monetization of WBA’s VillageMD businesses.
Notably, the sale price is below the price target for Walgreens of at least two Wall Street analysts even including the potential additional $3.00 per share in cash: Lisa Gill of J.P. Morgan ($15.00 per share target), and Charles Rhyee of TD Cowen ($15.00 per share target) (source: TipRanks). Additionally, the following three Wall Street analysts have $12.00 per share price targets for Walgreens: Ben Hendrix of RBC Capital, Elizabeth Anderson of Evercore ISI, and David Macdonald of Truist Financial (source: TipRanks).
Additionally, several shareholders on SeekingAlpha have expressed extreme disappointment in the sale price. For example, one investor with the screenname “evansd108” complained, “Getting robbed on this deal.” Another investor with the screenname “TradeJoeZ” commented, “Terrible deal for shareholders.” Finally, an investor with the screenname “Bitzap” lamented, “What a rip off.”
Finally, the sale price is well below Walgreens’ 52-week high of $22.05, and thus the deal appears highly opportunistic.
“We are investigating whether the Walgreens Board of Directors acted in the best interests of Walgreens shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to Walgreens shareholders, as well as whether all material information regarding the transaction has been fully disclosed.”
About Wohl & FruchterWohl & Fruchter LLP has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.
Contact:Wohl & Fruchter LLPJoshua E. Fruchter Toll Free 866.833.6245alerts@wohlfruchter.com www.wohlfruchter.com
Source: Wohl & Fruchter LLP
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This Story
WBA
|
Thread abonnieren
